CXCR1 and neoplasm: Other CXCR inhibitors, such as CXCR1 and CXCR2 antagonists like SCH527123, have demonstrated efficacy in preclinical models of various cancers, highlighting their potential in modulating the tumor microenvironment and reducing metastasis [97].